Badanie skuteczności Everolimusu i Lutetu (177Lu) oksodotreotydu u pacjentów z opornym oponiakiem stopnia 2 i 3

The study focuses on a type of brain tumor called meningioma, specifically grades 2 and 3, which are more challenging to treat. The purpose of the study is to evaluate the effectiveness of combining two treatments: Everolimus and 177Lu-DOTATATE. Everolimus is a medication taken in tablet form, while 177Lu-DOTATATE is given as an infusion directly into the bloodstream. These treatments are being tested together to see if they can help control the growth of the tumor.

Participants in the study will receive these treatments over a period of time. Everolimus is taken orally, and 177Lu-DOTATATE is administered through an intravenous infusion. The study will monitor how the tumor responds to this combination of treatments and will also track any side effects experienced by the participants. The goal is to determine if this combination can improve the condition of patients with these specific types of meningioma.

The study will last several months, during which participants will undergo regular check-ups and imaging tests to assess the tumor's response to the treatment. The results will help researchers understand if this combination of everolimus and 177Lu-DOTATATE is a viable option for treating grades 2 and 3 meningioma. Participants will be closely monitored to ensure their safety and to gather detailed information about the treatment's effects.